2005
DOI: 10.1007/s00280-005-0145-x View full text |Buy / Rent full text
|
|

Abstract: To quantitatively evaluate the extravasation, accumulation and selectivity to tumor tissues of liposomal vincristine (LV), dorsal skin-fold window chambers on athymic mice with or without LX-1, a human small cell lung cancer, xenograft implants and fluorescent intravital microscopy imaging were used. In vitro studies show that minimal loss of fluorescence marker DiI from liposomes occurs after 4 days of inoculation in murine plasma, and the release profiles of DiI-LV and LV were essentially the same with appro… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
3
2
2
14
0

Year Published

2010
2010
2016
2016

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

2
14
0
Order By: Relevance
“…The MTD for Marqibo was 2.5 mg/kg, a dose unachievable by standard vincristine treatment, where a MTD of 1.5 mg/kg was observed (Silverman and Deitcher, 2013). A similar result was reported using the LX-1 human small-cell lung carcinoma xenograft mouse model, in which Marqibo was shown to have greater antitumor activity than its free drug formulation at the equivalent dose of 1.0 mg/kg (Shan et al, 2006). This study also investigated the extravasation kinetics and accumulation of liposomal encapsulated vincristine using intravital microscopy imaging.…”
Section: Marqibosupporting
See 2 more Smart Citations
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 7 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…The MTD for Marqibo was 2.5 mg/kg, a dose unachievable by standard vincristine treatment, where a MTD of 1.5 mg/kg was observed (Silverman and Deitcher, 2013). A similar result was reported using the LX-1 human small-cell lung carcinoma xenograft mouse model, in which Marqibo was shown to have greater antitumor activity than its free drug formulation at the equivalent dose of 1.0 mg/kg (Shan et al, 2006). This study also investigated the extravasation kinetics and accumulation of liposomal encapsulated vincristine using intravital microscopy imaging.…”
Section: Marqibosupporting
“…This study also investigated the extravasation kinetics and accumulation of liposomal encapsulated vincristine using intravital microscopy imaging. Notably, significantly faster extravasation of liposomes was observed in tumor blood vessels than in normal tissues after a single dose of fluorescently labeled liposomal encapsulated vincristine (Shan et al, 2006). Furthermore, the accumulation of liposomal vincristine within the interstitium was ;70-fold higher in tumor tissue than in normal tissues at 1 hour and remained greater even after 48 hours (Shan et al, 2006).…”
Section: Marqibomentioning
See 1 more Smart Citation
“…The liposomal encapsulation of VCR protects the drug from the early phase of rapid elimination that is observed with nonliposomal VCR [15] . Previous studies have demonstrated that increasing VCR retention in liposomal systems improves the therapeutic index by increasing the duration of drug exposure to the tumor tissue [8,10,[16][17][18] . These PK properties of VSLI may potentially increase VCR accumulation in tumors and obtain greater efficacy over conventional VCR.…”
Section: Discussionmentioning
“…We tested equi-efficacious doses of the compounds based on TGI studies in mouse xenograft models. Vinblastine (0.5 mg/kg) and I-387 (10 mg/kg) were effective in MES-SA xenografts, and 0.4 to 1.6 mg/kg vincristine showed efficacy in numerous xenograft models (28)(29)(30). Vinblastine (0.5 mg/kg, every two days, i.p.)…”
Section: Discussionmentioning